Payload Information
General Information of This Payload
| Payload ID | PAY0MVQWE |
|||||
|---|---|---|---|---|---|---|
| Name | CL202203715A1 P7 |
|||||
| Synonyms |
CL202203715A1 P7
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C42H68N6O6S |
|||||
| Isosmiles | CCCCCCN(C([C@@H](NC([C@H]1CCCCN1C)=O)[C@H](CC)C)=O)[C@@H](C(C)C)C[C@@H](O)C2=NC(C(N[C@@H](CC3=CC=C(N)C=C3)CC(C)(C)C(O)=O)=O)=CS2 |
|||||
| InChI |
InChI=1S/C42H68N6O6S/c1-9-11-12-14-22-48(40(52)36(28(5)10-2)46-38(51)33-16-13-15-21-47(33)8)34(27(3)4)24-35(49)39-45-32(26-55-39)37(50)44-31(25-42(6,7)41(53)54)23-29-17-19-30(43)20-18-29/h17-20,26-28,31,33-36,49H,9-16,21-25,43H2,1-8H3,(H,44,50)(H,46,51)(H,53,54)/t28-,31-,33+,34+,35+,36-/m0/s1
|
|||||
| InChIKey |
ZFIKZKGHUPSRAC-OLIOEWOKSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
785.109 |
Polar area |
178.19 |
||
Complexity |
1469.906762 |
xlogp Value |
6.4395 |
|||
Heavy Count |
55 |
Rot Bonds |
22 |
|||
Hbond acc |
9 |
Hbond Donor |
5 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
TRSQ-ZP3A-LP12 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.029 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 18% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP26 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.078 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 20% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
TRSQ-ZP3A-LP13 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.083 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 19% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
CTRL-ZP3A-LP26 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
58.334 nM
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The anti-proliferation test was carried out with SK-BR-3 human breast cancer cell line. Cells were grown in McCoy's 5a medium supplemented with 21% FBS,penicillin/streptomycin and L-glutamine.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||